Compare HNST & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HNST | ZVRA |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.8M | 562.2M |
| IPO Year | 2021 | 2015 |
| Metric | HNST | ZVRA |
|---|---|---|
| Price | $5.99 | $12.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $3.05 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 3.4M | 867.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | 0.09 | ★ 0.74 |
| Revenue | ★ $371,317,000.00 | $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | $5.93 | $53.42 |
| P/E Ratio | $65.22 | ★ $16.82 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $2.07 | $7.16 |
| 52 Week High | $5.96 | $15.04 |
| Indicator | HNST | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 72.78 | 60.29 |
| Support Level | $3.22 | $12.18 |
| Resistance Level | N/A | $14.27 |
| Average True Range (ATR) | 0.27 | 0.37 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 93.23 | 93.38 |
The Honest Co Inc is a personal care company dedicated to creating cleanly-formulated and sustainably-designed products for everyone from babies to adults. By combining thoughtful design with science-based innovation, the company delivers personal care products for everyone from babies to adults, spanning categories across wipes, personal care, diapers, and beauty. It has three product categories namely; Diapers and Wipes, Skin and Personal Care, and Household and Wellness, out of which the majority of its revenue is generated from the sale of diapers and wipes. The company operates only in the United States.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.